Literature DB >> 20361889

Adverse cutaneous reactions to psychopharmaceuticals.

Vesna Lamer1, Jasna Lipozencić, Petra Turcić.   

Abstract

Adverse cutaneous reactions to psychoactive drugs are common. They disturb and interrupt therapy often leading to non-compliance. The majority of adverse cutaneous reactions are benign if they are promptly recognized. Withdrawal of suspected drug is the first step for consequent treatment. As some adverse cutaneous reactions are life threatening, the most important action is to discontinue the drug usage promptly, thus minimizing morbidity. It is very important for physicians to be aware of the potentially serious adverse skin reactions to psychoactive drugs. Patients must be provided with simple information on these adverse effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20361889

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  5 in total

1.  Effect of thioridazine on antioxidant status of HEMn-DP melanocytes.

Authors:  Michał Otręba; Artur Beberok; Dorota Wrześniok; Jakub Rok; Ewa Buszman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-24       Impact factor: 3.000

2.  In vitro melanogenesis inhibition by fluphenazine and prochlorperazine in normal human melanocytes lightly pigmented.

Authors:  Michał Otręba; Artur Beberok; Dorota Wrześniok; Ewa Buszman
Journal:  Daru       Date:  2018-07-24       Impact factor: 3.117

3.  Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders.

Authors:  Kimberly Tallian
Journal:  Ment Health Clin       Date:  2018-03-23

4.  Serum drug level-related sodium valproate-induced hair loss.

Authors:  Suresh K Ramakrishnappa; Mahesh N Belhekar
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

5.  Use of psychiatric drugs in Dermatology.

Authors:  Magda Blessmann Weber; Júlia Kanaan Recuero; Camila Saraiva Almeida
Journal:  An Bras Dermatol       Date:  2020-02-18       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.